High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants

Atherosclerosis

Volumn 200, Issue 1, 2008, Pages 161-167

  van Acker, Bernadette A C ^a   Botma, Gert Jan ^a   Zwinderman, Aeilko H ^b   Kuivenhoven, Jan Albert ^b   Dallinga Thie, Geesje M ^a,b   Sijbrands, Eric J G ^a   Boer, Jolanda M A ^c   Seidell, Jacob C ^c,d   Jukema, J Wouter ^e,f   Kastelein, John J P ^b   Jansen, Hans ^a   Verhoeven, Adrie J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; Coronary artery disease; Genetics; Hepatic lipase; High density lipoprotein; Reverse cholesterol transport

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; LIPASE; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 49749097248     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.11.019     Document Type: Article

References (31)

1. Gordon D.J., and Rifkind B.M. High density lipoprotein-the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
2. Nofer J.R., Kehrel B., Fobker M., et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161 (2002) 1-16
3. Bisoendial R.J., Hovingh G.K., Levels J.H., et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107 (2003) 2944-2948
4. Tall A.R. An overview of reverse cholesterol transport. Eur Heart J 19 (1998) A31-A35
5. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
6. Cohen J.C., Kiss R.C., Pertsemlidis A., et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305 (2004) 869-872
7. Boekholdt S.M., Souverein O.W., Tanck M.W.T., et al. Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. Clin Genet 69 (2006) 263-270
8. Boekholdt S.M., Sacks F.M., Jukema J.W., et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111 (2005) 278-287
9. Guerra R., Wang J., Grundy S.M., and Cohen J.C. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high-density lipoprotein cholesterol. Proc Natl Acad Sci USA 94 (1997) 4532-4537
10. Jansen H., Verhoeven A.J.M., and Sijbrands E.J.G. Hepatic lipase: a pro- or anti-atherogenic protein?. J Lipid Res 43 (2002) 1352-1362
11. Jansen H., Verhoeven A.J.M., Weeks L., et al. Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol 17 (1997) 2837-2842
12. Isaacs A., Sayed-Tabatabaei F.A., Njajou O.T., Witteman J.C., and van Duijn C.M. The -514 C→T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab 89 (2004) 3858-3863
13. Zambon A., Deeb S.S., Hokanson J.E., Brown B.G., and Brunzell J.D. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 18 (1998) 1723-1729
14. Zambon A., Deeb S.S., Brown B.G., Hokanson J.E., and Brunzell J.D. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 103 (2001) 792-798
15. Frisdal E., Klerkx A.H.E.M., Le Goff W., et al. Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Mol Genet 14 (2005) 2607-2618
16. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
17. Hirano K., Yamashita S., Kuga Y., et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 15 (1995) 1849-1856
18. Talmud P.J., Hawe E., Robertson K., et al. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet 66 (2002) 111-124
19. Takata M., Inazu A., Katsuda S., et al. CETP (cholesteryl ester transfer protein) promoter -1337 C→T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia. Clin Sci (Lond) 111 (2006) 325-331
20. Isaacs A., Aulchenko Y.S., Hofman A., et al. Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum HDL-c levels. J Clin Endocrinol Metab 92 (2007) 2680-2687
21. Whiting B.M., Anderson J.L., Muhlestein J.B., et al. Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. Am Heart J 150 (2005) 243-250
22. Jukema J.W., Bruschke A.V.G., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 91 (1995) 2528-2540
23. Verschuren W.M.M., van Leer E.M., Blokstra A., et al. Cardiovascular risk factors in the Netherlands. Neth J Cardiol 4 (1993) 205-210
24. Müllenbach R., Lagoda P.J., and Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 5 (1989) 391
25. Boekholdt S.M., and Thompson J.F. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 44 (2003) 1080-1093
26. Blankenberg S., Rupprecht H.J., Bickel C., et al. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol 41 (2003) 1983-1989
27. Carr M.C., Ayyobi A.F., Murdoch S.J., Deeb S.S., and Brunzell J.D. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol 22 (2002) 667-673
28. Föger B., Chase M., Amar M.J., et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 274 (1999) 36912-36920
29. von Eckardstein A., Nofer J.-R., and Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21 (2001) 13-27
30. De Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F.H., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. A randomised phase II dose-response study. Circulation 105 (2002) 2159-2165
31. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260